Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy

Irinotecan treats a range of solid tumors, but its effectiveness is severely limited by gastrointestinal (GI) tract toxicity caused by gut bacterial β-glucuronidase (GUS) enzymes. Targeted bacterial GUS inhibitors have been shown to partially alleviate irinotecan-induced GI tract damage and resultan...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhatt, Aadra P., Pellock, Samuel J., Biernat, Kristen A., Walton, William G., Wallace, Bret D., Creekmore, Benjamin C., Letertre, Marine M., Swann, Jonathan R., Wilson, Ian D., Roques, Jose R., Darr, David B., Bailey, Sean T., Montgomery, Stephanie A., Roach, Jeffrey M., Azcarate-Peril, M. Andrea, Sartor, R. Balfour, Gharaibeh, Raad Z., Bultman, Scott J., Redinbo, Matthew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2020
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132129/
https://www.ncbi.nlm.nih.gov/pubmed/32170007
http://dx.doi.org/10.1073/pnas.1918095117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132129/
https://www.ncbi.nlm.nih.gov/pubmed/32170007
http://dx.doi.org/10.1073/pnas.1918095117

Ejemplares similares